The U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) phase 3 studies investigated the efficacy and safety of upadacitinib, an oral, selective JAK inhibitor in patients with moderate-to-severe Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss his sub-analysis of the data from U-EXCEL […]

Ligelizumab is a monoclonal antibody recently investigated in the phase 3 PEARL-1 and PEARL-2 studies for the treatment of chronic spontaneous urticaria (ClinicalTrials.gov Identifiers: NCT03580369 & NCT03580356). In this touchIMMUNOLOGY interview, we spoke with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, São Paulo, Brazil) around the rationale for investigating ligelizumab in this […]

Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]

Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, USA) around the recent advances made in biomarkers and targeted therapies for inflammatory skin diseases, […]

The term spondyloarthritis (SpA) encompasses a number of disease entities that share common clinical, biological and genetic characteristics. Common clinical features include inflammation in the axial skeleton, including the spine and sacroiliac joints, and inflammation of peripheral musculoskeletal structures such as arthritis, enthesitis and dactylitis.1 The disease is therefore divided by (predominantly) axial or peripheral manifestations. […]

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a spectrum of disorders primarily affecting the small blood vessels in various organs. It often affects the kidneys, causing rapidly progressive renal failure due to necrotizing crescentic glomerulonephritis. Another major cause of mortality in AAV is life-threatening pulmonary haemorrhage. Historically, AAV has been divided into granulomatosis with polyangiitis […]

Reducing the risk of rheumatic and musculoskeletal disease (RMD) is crucial to prevent associated chronic disease burden. However, the process is complex because the aetiopathological factors contributing to disease onset are not entirely understood. Healthy eating based on the Mediterranean diet (MD) can effectively prevent many chronic conditions and, potentially, RMD. Together with physical activity, […]

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) includes several distinct clinical entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and renal-limited vasculitis. What all these diseases have in common is the presence of serum autoantibodies, designated as ANCA, that react with antigens in the cytoplasm of neutrophilic granulocytes and monocytes.1,2 The […]